Value of Utilizing Matching-Adjusted Indirect Comparisons (MAICs) in Psoriasis

In this episode, "Value of Utilizing Matching-Adjusted Indirect Comparisons (MAICs) in Psoriasis," the expert dermatologists explore the methodology behind matching adjusted indirect comparisons and their practical value in guiding evidence based treatment decisions for plaque psoriasis.

The panel opens by establishing that while head to head clinical trials remain the gold standard for comparing therapies, they are not always available. In their absence, matching adjusted indirect comparisons offer a more statistically rigorous alternative to simply comparing results across separate trials. The methodology is explained clearly: when patient level data is available for one drug and only aggregate mean demographic data is available for another, the patient level dataset can be adjusted and matched to the population characteristics of the comparator drug. This process accounts for known variables that can influence treatment outcomes, such as prior biologic exposure, disease severity, and the prevalence of psoriatic arthritis in the study population, resulting in a more balanced and meaningful comparison between the two therapies.

The panel emphasizes that matching adjusted indirect comparisons are not only valuable to manufacturers seeking to demonstrate their drug's performance to payers, but also serve as an important clinical decision making tool for dermatologists navigating treatment sequencing without direct comparative data. The discussion concludes with the panel reinforcing that patients who receive the most effective drug first tend to achieve better long term outcomes than those who cycle through multiple therapies, making the ability to identify a preferred agent through indirect comparison models a meaningful advantage in optimizing patient care.

The next episode in this series, "Evaluating Psoriasis Therapies using MAICs," features the panelists advancing their conversation on psoriasis and focusing on recent MAIC analyses comparing key IL-23 inhibitors and other biologic classes, highlighting how these indirect comparisons have demonstrated statistically significant efficacy differences across PASI endpoints and have since been validated by dedicated head to head clinical trials.